Bone Biologics Corporation

NasdaqCM BBLG

Bone Biologics Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Bone Biologics Corporation Gross Profit Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: BBLG

Bone Biologics Corporation

CEO	Mr. Jeffrey Frelick
IPO Date	Oct. 13, 2021
Location	United States
Headquarters	2 Burlington Woods Drive
Employees	2
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Composite Materials Medical Instruments Plastics Robotics

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key trends

Past 5 years